Market capitalization | $24.43m |
Enterprise Value | $12.11m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 1.24 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-35.48m |
Free Cash Flow (TTM) Free Cash Flow | $-26.03m |
Cash position | $33.98m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
4 Analysts have issued a Unity Biotechnology, Inc. forecast:
4 Analysts have issued a Unity Biotechnology, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.99 -0.99 |
38%
38%
|
|
EBITDA | -35 -35 |
21%
21%
|
EBIT (Operating Income) EBIT | -35 -35 |
22%
22%
|
Net Profit | -31 -31 |
40%
40%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Unity Biotechnology, Inc. operates as a biotechnology company engaged in the research and development of therapeutics to extend the human health span. The company was founded by Nathaniel Eames David, Jan van Deursen, Judith Campisi and Daohong Zhou on March 30, 2009 and is headquartered in Brisbane, CA.
Head office | United States |
CEO | Anirvan Ghosh |
Employees | 19 |
Founded | 2009 |
Website | www.unitybiotechnology.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.